29.03.2011 15:00:00

Agilent Technologies and National University of Singapore Sign Research Collaboration Agreement for Lipidomics Research

Agilent Technologies Inc. (NYSE:A) and the National University of Singapore (NUS) today announced an agreement to develop expertise and knowledge in the area of analytical lipidomics. The goal of the partnership is to develop workflow solutions that enable researchers to more accurately understand disease states.

Under the terms of the agreement, Agilent’s provision of sophisticated test and measurement instruments will be housed in the NUS Center for Lipidomics within the university’s Life Sciences Institute. Headed by Associate Professor Markus Wenk, NUS Department of Biochemistry and Department of Biological Sciences, this center will host researchers and scientists from clinical and commercial organizations in Singapore and the Asia Pacific region. The center grew out of a competitive five-year research program and promises to be a global magnet for collaborating parties in lipidomics.

The collaboration will help to further advances in the emerging field of lipidomics, which may lead to the creation of new classes of biomedical research tools and therapies. The NUS Industry Liaison Office has been actively guiding the researchers and facilitating their work with industry to create win-win relationships with companies such as Agilent.

"Integrated tool development programs, such as this new Center for Lipidomics, greatly support applications in life and environmental sciences,” said Professor Barry Halliwell, NUS deputy president (Research and Technology). "We are delighted by the substantial industry interest and welcome Agilent as a partner in this endeavor.”

Agilent will support NUS with highly specialized instruments for the separation and analysis of lipids from complex mixtures using robotic systems and the latest bioinformatics software tools and electronic lab notebooks. The company will also provide NUS access to its scientists in Asia and the United States. NUS will serve as a reference site for Agilent and allow the company to better understand the needs of the research community. Agilent will use what it learns to further develop and enhance its instruments.

"Lipids play crucial roles in pathophysiology,” said Professor John Wong, dean of the NUS Yong Loo Lin School of Medicine. "The close proximity of this new center to clinical research and patient care at the National University Health System places us in a unique position for knowledge creation and translation in biomedicine.”

Additionally, both Agilent and NUS have agreed to explore opportunities in the field of lipidomics through collaborative research projects, short-term consultancies, customized training programs and workshops, and participation at industry seminars and conferences to advance the level of knowledge in the field of lipidomics.

"This strategic partnership with NUS will raise the level of knowledge for lipidomics and potentially pave the way for developments in related fields of research such as life sciences, nutritional sciences or environment sciences,” said Rod Minett, Agilent’s general manager, Life Sciences Group, South Asia Pacific and Korea. "We will collect insights into the use of our instruments in this complex research field and look to further develop and enhance our capabilities, not only in lipidomics but also in related fields of research.”

"This collaboration will further strengthen Agilent’s worldwide leadership in the field of metabolomics, which is a key strategic initiative for our company,” said Rudolf Grimm, Ph.D., Agilent’s director of science and technology and collaborations manager, Asia Pacific.

More information about Agilent’s life sciences products and services is available at www.chem.agilent.com.

About National University of Singapore

A leading global university centered in Asia, the National University of Singapore (NUS) is Singapore’s flagship university. NUS offers a global approach to education and research, with a focus on Asian perspectives and expertise. NUS has 14 faculties and schools across three campuses. Its transformative education includes a broad-based curriculum underscored by multi-disciplinary courses and cross-faculty enrichment. Over 36,000 students from 100 countries enrich the community with their diverse social and cultural perspectives.

NUS has three Research Centres of Excellence (RCE) and 22 university-level research institutes and centres. It is also a partner in Singapore’s 5th RCE. NUS shares a close affiliation with 16 national-level research institutes and centres. Research activities are strategic and robust, and NUS is well-known for its research strengths in engineering, life sciences and biomedicine, social sciences and natural sciences. It also strives to create a supportive and innovative environment to promote creative enterprise within its community. More information is available at www.nus.edu.sg.

About NUS Yong Loo Lin School of Medicine

Established in 1905, the NUS Yong Loo Lin School of Medicine (YLLSoM) was the first institution of higher learning in Singapore and the genesis of what would become the National University of Singapore. The school offers one of the finest undergraduate medical programs in the Asia Pacific region and commands international recognition and respect.

The school strives to fulfill its tripartite mission of providing excellent clinical care, training the next generation of health-care professionals, and fostering research that will transform the practice of medicine. It plays a pivotal role in producing future leaders in health-care delivery, discovery and public service as well as in Singapore’s Biomedical Sciences Initiative and Singapore Medicine, a medical tourism initiative. The school’s 17 departments in the basic sciences and clinical specialties work closely with the Alice Lee Centre for Nursing Studies, the Centre for Biomedical Ethics, and the Centre of Excellence for Health Services Research to ensure that teaching and research are aligned and relevant to Singapore’s health-care needs.

More information about YLLSoM is available at medicine.nus.edu.sg/corporate.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Agilent Technologies Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Agilent Technologies Inc. 130,58 -0,20% Agilent Technologies Inc.

Indizes in diesem Artikel

S&P 500 5 998,74 -0,38%